Aethlon Medical, Inc. announced on January 29, 2025, a significant milestone with the treatment of the first patient in its Australian safety, feasibility, and dose-finding clinical trial of the Hemopurifier. The patient was treated at the Royal Adelaide Hospital.
The patient, who was enrolled on October 29, 2024, had progressive disease following a two-month run-in period of anti-PD-1 therapy (Nivolumab). The 4-hour Hemopurifier treatment was completed on January 29, 2025, and the patient tolerated the procedure without complications.
This treatment represents a critical step in the clinical development of the Hemopurifier in Oncology. The company anticipates receiving data from this first treatment cohort to gain insights into the device's potential to reduce tumor-derived extracellular vesicles and enhance T-cell activity against tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.